Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Radius Health, Inc.RDUS · Entity 124173 | Director | February 20, 2020 | February 24, 2020 |
| Seres Therapeutics, Inc.MCRB · Entity 7191 | Director | July 08, 2026 | July 10, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP, Chief Commercial Officer | October 19, 2009 | October 21, 2009 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Radius Health, Inc.
Report date February 20, 2020 · Filed February 24, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,000 |
Reported balance
After 2020-02-20 transaction · row 1
1 source rowRow 1 · 2020-02-20 · Grant · Acquired 5,500 · Balance 11,000 F1: The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. The restricted stock units vest in full on February 20, 2021, subject to continued service with RDUS through such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.96 · Expires 2030-02-20 | Direct | 10,000 |
Reported balance
After 2020-02-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-02-20 · Grant · Acquired 10,000 · Balance 10,000 F2: The option vests in full on February 20, 2021, subject to continued service with RDUS through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. The restricted stock units vest in full on February 20, 2021, subject to continued service with RDUS through such date.
F2: The option vests in full on February 20, 2021, subject to continued service with RDUS through such date.
Seres Therapeutics, Inc.
Report date July 08, 2026 · Filed July 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.14 · Expires 2036-07-07 | Direct | 6,500 |
Reported balance
After 2026-07-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-08 · Grant · Acquired 6,500 · Balance 6,500 F1: The option vests and becomes exercisable on the earlier to occur of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable on the earlier to occur of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026.
VERTEX PHARMACEUTICALS INC / MA
Report date October 19, 2009 · Filed October 21, 2009
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 59,880 |
Reported balance
After 2009-10-19 transaction · row 1
1 source rowRow 1 · 2009-10-19 · Sale · Disposed 1,500 · Balance 59,880 F1: Transaction made pursuant to Mr. Graves' company approved trading plan established under Rule 10b5-1. F2: Open market sales reported on this line occurred at a weighted average price of $34.70 (range $34.56 to $34.83). F3: Mr. Graves undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 605 |
Reported balance
Holding disclosure · report date 2009-10-19 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 605 |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Mr. Graves' company approved trading plan established under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $34.70 (range $34.56 to $34.83).
F3: Mr. Graves undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ACHILLION PHARMACEUTICALS INC
Report date January 28, 2020 · Filed January 29, 2020
Section 16 reporting ended · disclosed 2020-01-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-01-28 transaction · row 1
1 source rowRow 1 · 2020-01-28 · Disposition to issuer · Disposed 22,709 · Balance 0 F1: Disposed of pursuant to the merger agreement (the "Merger Agreement") among Achillion Pharmaceuticals, Inc. ("Achillion"), Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. In addition to the cash consideration of $6.30 per share, each shareholder will also receive one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.54 · Expires 2026-01-25 | Direct | 0 |
Reported balance
After 2020-01-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-01-28 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.12 · Expires 2022-06-11 | Direct | 0 |
Reported balance
After 2020-01-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-01-28 · Disposition to issuer · Disposed 135,000 · Balance 0 F2: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.09 · Expires 2027-01-19 | Direct | 0 |
Reported balance
After 2020-01-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-01-28 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.02 · Expires 2023-12-17 | Direct | 0 |
Reported balance
After 2020-01-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-01-28 · Disposition to issuer · Disposed 25,000 · Balance 0 F2: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2028-02-09 | Direct | 0 |
Reported balance
After 2020-01-28 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-01-28 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.18 · Expires 2029-01-23 | Direct | 0 |
Reported balance
After 2020-01-28 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-01-28 · Disposition to issuer · Disposed 42,000 · Balance 0 F2: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the merger agreement (the "Merger Agreement") among Achillion Pharmaceuticals, Inc. ("Achillion"), Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. In addition to the cash consideration of $6.30 per share, each shareholder will also receive one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471.
F2: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 20, 2008 Filed May 22, 2008 13:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 151 | $27.46 | $4,146.46 |
DisclosureSEC source: 0000875320-08-000031 · edgar.xml · nonDerivative · entry 6 Graves Kurt · CIK 0001406337 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,577 F1 · kind: Transaction made pursuant to Mr. Graves' company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 20, 2008 Filed May 22, 2008 13:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 151 | $27.74 | $4,188.74 |
DisclosureSEC source: 0000875320-08-000031 · edgar.xml · nonDerivative · entry 5 Graves Kurt · CIK 0001406337 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,728 F1 · kind: Transaction made pursuant to Mr. Graves' company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 20, 2008 Filed May 22, 2008 13:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 302 | $27.61 | $8,338.22 |
DisclosureSEC source: 0000875320-08-000031 · edgar.xml · nonDerivative · entry 4 Graves Kurt · CIK 0001406337 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,879 F1 · kind: Transaction made pursuant to Mr. Graves' company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 20, 2008 Filed May 22, 2008 13:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 151 | $27.59 | $4,166.09 |
DisclosureSEC source: 0000875320-08-000031 · edgar.xml · nonDerivative · entry 3 Graves Kurt · CIK 0001406337 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,181 F1 · kind: Transaction made pursuant to Mr. Graves' company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 20, 2008 Filed May 22, 2008 13:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 134 | $27.58 | $3,695.72 |
DisclosureSEC source: 0000875320-08-000031 · edgar.xml · nonDerivative · entry 2 Graves Kurt · CIK 0001406337 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,332 F1 · kind: Transaction made pursuant to Mr. Graves' company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 20, 2008 Filed May 22, 2008 13:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 169 | $27.50 | $4,647.50 |
DisclosureSEC source: 0000875320-08-000031 · edgar.xml · nonDerivative · entry 1 Graves Kurt · CIK 0001406337 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,466 F1 · kind: Transaction made pursuant to Mr. Graves' company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $27.63 | $5,526.00 |
DisclosureSEC source: 0000875320-08-000025 · edgar.xml · nonDerivative · entry 8 Graves Kurt · CIK 0001406337 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,123 F1 · kind: Transaction made pursuant to Mr. Grave's company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $27.47 | $5,494.00 |
DisclosureSEC source: 0000875320-08-000025 · edgar.xml · nonDerivative · entry 7 Graves Kurt · CIK 0001406337 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,323 F1 · kind: Transaction made pursuant to Mr. Grave's company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $27.38 | $2,738.00 |
DisclosureSEC source: 0000875320-08-000025 · edgar.xml · nonDerivative · entry 6 Graves Kurt · CIK 0001406337 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,523 F1 · kind: Transaction made pursuant to Mr. Grave's company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $27.35 | $2,735.00 |
DisclosureSEC source: 0000875320-08-000025 · edgar.xml · nonDerivative · entry 5 Graves Kurt · CIK 0001406337 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,623 F1 · kind: Transaction made pursuant to Mr. Grave's company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1 | $27.12 | $27.12 |
DisclosureSEC source: 0000875320-08-000025 · edgar.xml · nonDerivative · entry 4 Graves Kurt · CIK 0001406337 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,723 F1 · kind: Transaction made pursuant to Mr. Grave's company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 148 | $27.09 | $4,009.32 |
DisclosureSEC source: 0000875320-08-000025 · edgar.xml · nonDerivative · entry 3 Graves Kurt · CIK 0001406337 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,724 F1 · kind: Transaction made pursuant to Mr. Grave's company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2 | $27.07 | $54.14 |
DisclosureSEC source: 0000875320-08-000025 · edgar.xml · nonDerivative · entry 2 Graves Kurt · CIK 0001406337 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,872 F1 · kind: Transaction made pursuant to Mr. Grave's company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $27.00 | $5,400.00 |
DisclosureSEC source: 0000875320-08-000025 · edgar.xml · nonDerivative · entry 1 Graves Kurt · CIK 0001406337 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,874 F1 · kind: Transaction made pursuant to Mr. Grave's company approved trading plan established under Rule 10b5-1. Read SEC document |
| February 07, 2008 Filed Feb 11, 2008 20:58 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 90,625 | $0.00 Strike: $18.93 | $0.00 |
DisclosureSEC source: 0000875320-08-000011 · edgar.xml · derivative · entry 2 Graves Kurt · CIK 0001406337 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,625 Underlying: Common Stock · 90,625 shares Expires 2018-02-06 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments from 02/07/2008, subject to shareholder approval. Read SEC document |
| February 07, 2008 Filed Feb 11, 2008 20:58 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 12,084 | $0.01 | $120.84 |
DisclosureSEC source: 0000875320-08-000011 · edgar.xml · nonDerivative · entry 1 Graves Kurt · CIK 0001406337 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,074 F1 · shares: Stock grant made under 2006 Stock and Option Plan, vesting on 2/7/2012, subject to acceleration upon achievement of certain performance-based milestones. Read SEC document |
| November 06, 2007 Filed Nov 7, 2007 21:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | PurchaseCommon Stock | 790 | $25.25 | $19,947.50 |
DisclosureSEC source: 0000875320-07-000104 · edgar.xml · nonDerivative · entry 7 Graves Kurt · CIK 0001406337 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,990 Read SEC document |
| November 06, 2007 Filed Nov 7, 2007 21:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | PurchaseCommon Stock | 1,308 | $25.14 | $32,883.12 |
DisclosureSEC source: 0000875320-07-000104 · edgar.xml · nonDerivative · entry 6 Graves Kurt · CIK 0001406337 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,200 Read SEC document |
| November 06, 2007 Filed Nov 7, 2007 21:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | PurchaseCommon Stock | 300 | $25.15 | $7,545.00 |
DisclosureSEC source: 0000875320-07-000104 · edgar.xml · nonDerivative · entry 5 Graves Kurt · CIK 0001406337 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,892 Read SEC document |
| November 06, 2007 Filed Nov 7, 2007 21:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | PurchaseCommon Stock | 100 | $25.12 | $2,512.00 |
DisclosureSEC source: 0000875320-07-000104 · edgar.xml · nonDerivative · entry 4 Graves Kurt · CIK 0001406337 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,592 Read SEC document |
| November 06, 2007 Filed Nov 7, 2007 21:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | PurchaseCommon Stock | 1,000 | $25.11 | $25,110.00 |
DisclosureSEC source: 0000875320-07-000104 · edgar.xml · nonDerivative · entry 3 Graves Kurt · CIK 0001406337 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,492 Read SEC document |
| November 06, 2007 Filed Nov 7, 2007 21:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | PurchaseCommon Stock | 100 | $25.10 | $2,510.00 |
DisclosureSEC source: 0000875320-07-000104 · edgar.xml · nonDerivative · entry 2 Graves Kurt · CIK 0001406337 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,492 Read SEC document |
| November 06, 2007 Filed Nov 7, 2007 21:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | PurchaseCommon Stock | 392 | $25.09 | $9,835.28 |
DisclosureSEC source: 0000875320-07-000104 · edgar.xml · nonDerivative · entry 1 Graves Kurt · CIK 0001406337 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,392 Read SEC document |
| July 17, 2007 Filed Jul 18, 2007 17:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 100,000 | $0.00 Strike: $28.85 | $0.00 |
DisclosureSEC source: 0000875320-07-000082 · edgar.xml · derivative · entry 3 Graves Kurt · CIK 0001406337 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2017-07-16 F3 · shares: Right to buy under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments over four years. Read SEC document |
| July 17, 2007 Filed Jul 18, 2007 17:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 18,000 | $0.01 | $180.00 |
DisclosureSEC source: 0000875320-07-000082 · edgar.xml · nonDerivative · entry 2 Graves Kurt · CIK 0001406337 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 F2 · shares: Stock grant made under 2006 Stock and Option Plan vesting in 12 equal quarterly installments over three years. Read SEC document |
| July 17, 2007 Filed Jul 18, 2007 17:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 30,000 | $0.01 | $300.00 |
DisclosureSEC source: 0000875320-07-000082 · edgar.xml · nonDerivative · entry 1 Graves Kurt · CIK 0001406337 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · shares: Stock grant made under 2006 Stock and Option Plan vesting in four equal annual installments over four years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.